* Q3 loss $0.19/shr vs $0.26/shr yr ago
* Revenue down 21 pct
* R&D expenses down 30 pct
Nov 11 (Reuters) - Canadian biopharmaceuticals company Aeterna Zentaris Inc AEZ.TO AEZS.O narrowed its third-quarter loss, helped by lower research and development expenses.
The company said loss was $11.3 million, or 19 cents per share, for the quarter ending Sept. 30, 2009, compared with a loss of $13.9 million, or 26 cents per share, a year ago.
Revenue was down about 21 percent to $8.6 million, mainly due to lower royalty revenue, while R&D expenses dropped about 30 percent to $9.7 million.
Analysts were expecting a loss of 21 cents, excluding special items, on revenue of $8 million, according to Thomson Reuters I/B/E/S.
Shares of the Quebec-based company closed at C$1.13 Tuesday on the Toronto Stock Exchange. (Reporting by Amit Kumar in Bangalore; Editing by Anil D'Silva)